Who Owns SI-Bone Company?

SI-Bone Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns SI-Bone?

Understanding the ownership structure of a company is crucial for any investor or business strategist. SI-BONE, a medical device innovator specializing in SI-Bone SWOT Analysis, presents a compelling case study in how ownership transitions can shape a company's destiny. From its inception to its current status as a publicly traded entity, the evolution of SI-Bone's ownership tells a story of strategic shifts and market dynamics.

This analysis will explore the intricate details of SI-Bone's ownership, from the initial vision of founder Mark A. Reiley to the present-day influence of its diverse shareholder base. We'll examine the impact of its IPO and the key players who have shaped the company's trajectory, providing insights into the forces driving SI-Bone's performance in the market for sacroiliac joint pain treatment. Discover the answers to questions like: Who founded SI-Bone and who are SI-Bone investors?

The origins of the SI-Bone company trace back to April 2008, when it was founded by Mark A. Reiley. The company's journey began with a focus on addressing Sacroiliac joint pain treatment, a condition that often requires innovative medical solutions. Reiley brought a wealth of experience to the table, having previously invented kyphoplasty, a procedure for vertebral compression fractures, and founded INBONE Technologies.

SI-Bone's emergence as a standalone entity was a result of Wright Medical acquiring INBONE Technologies, which led to the spin-out of SI-Bone. This pivotal moment set the stage for the company's dedicated focus on Sacroiliac joint fusion and the development of related medical devices. The early stages were marked by significant financial backing from venture capital firms.

During its initial private phase, the SI-Bone company secured a total of $103 million in funding across seven rounds from a group of eleven investors. This early financial support was critical in fueling the company's development and commercialization efforts. The early funding rounds demonstrate a reliance on venture capital to fuel its development and commercialization efforts.

Founder's Expertise

Mark A. Reiley, the founder of SI-Bone, brought extensive experience in medical device innovation. His previous work included inventing kyphoplasty and founding INBONE Technologies.

Spin-Out from INBONE

SI-Bone was formed as a spin-out after Wright Medical acquired INBONE Technologies. This transition allowed SI-Bone to concentrate on Sacroiliac joint fusion.

Early Funding Rounds

The company raised a total of $103 million in funding over seven rounds. This early funding was crucial for the company's initial growth and development.

Key Investors

Early investors included venture capital firms like Skyline Ventures, Orbimed, and Novo A/S. These investors provided significant financial backing.

Focus on SI Joint Fusion

The early investments and Reiley's vision established SI-Bone's focus on minimally invasive SI joint fusion. This focus has been central to the company's mission.

Early Financial Support

The early financial support from investors enabled SI-Bone to develop and commercialize its products. This funding was essential for the company's early success.

SI-Bone Ownership and Early Investment Highlights

The initial funding rounds for the SI-Bone company were heavily reliant on venture capital, with significant contributions from firms like Skyline Ventures, Orbimed, and Novo A/S. While the exact ownership percentages at the company's inception are not publicly available, these early investments were instrumental in shaping SI-Bone's strategic direction and product development. Understanding the SI-Bone ownership structure and the early SI-Bone investors provides valuable insight into the company's foundational years and its approach to addressing Sacroiliac joint pain treatment. For more information on the company's market positioning, consider exploring the Target Market of SI-Bone.

• The company was founded in April 2008 by Mark A. Reiley.
• SI-Bone raised $103 million in funding across seven rounds.
• Key early investors included Skyline Ventures, Orbimed, and Novo A/S.
• The focus was on minimally invasive SI joint fusion.

SI-Bone SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of SI-BONE, Inc. underwent a significant transformation with its Initial Public Offering (IPO) on October 17, 2018. Before this, the company operated as a privately held entity, backed by venture capital. The IPO involved the offering of 7.2 million shares, priced at $15.00 per share, which resulted in approximately $108 million in proceeds. After accounting for underwriting discounts and other expenses, SI-BONE received net proceeds of roughly $113.4 million. The shares began trading on The Nasdaq Global Market under the ticker symbol 'SIBN', marking a pivotal shift to public ownership. This transition opened the door for broader investor participation and increased scrutiny from the public markets.

The shift to a publicly traded company had a substantial impact on the ownership landscape. The IPO facilitated the entry of numerous institutional investors, who now hold a dominant position in the company. This change in ownership structure has implications for corporate strategy, governance, and the overall direction of the company. The evolution from a venture-backed startup to a publicly listed entity highlights the growth trajectory and the increasing investor interest in the company's Sacroiliac joint fusion technology and SI-Bone investors.

As of May 2025, institutional investors maintain a substantial presence, holding 95.82% of SI-BONE's shares, unchanged from April 2025. Mutual funds account for 79.85% of the shares, also unchanged in May 2025. Insider holdings have slightly decreased to 6.04% in May 2025, indicating some shifts in ownership among company insiders. Major institutional shareholders as of March 31, 2025, include BlackRock, Inc., Orbimed Advisors LLC, and Brown Advisory Inc., among others. The concentration of ownership among these major shareholders suggests a significant influence on the company's strategic direction. For more insights into the company's marketing approach, consider reading about the Marketing Strategy of SI-Bone.

Key Takeaways on SI-Bone Ownership

SI-BONE's ownership structure has evolved significantly since its IPO in 2018.

• Institutional investors hold the majority of shares, influencing company strategy.
• Insider holdings have seen slight changes, reflecting internal ownership dynamics.
• The company's transition to public markets has broadened its investor base.
• Understanding the ownership structure is crucial for evaluating the company's performance and future prospects, especially for those interested in SI-Bone stock.

SI-Bone PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

As of March 28, 2025, the Board of Directors of the SI-Bone company comprises eight members. Each director serves a one-year term, with their tenure concluding at the subsequent annual stockholders' meeting. Directors can only be removed if there is cause, requiring an affirmative vote of at least 75% of the total votes cast by all stockholders. This structure ensures a degree of stability and accountability in the company's leadership.

The current board members include Jeffrey Dunn, who serves as Chairman of the Board, and Laura Francis, the Chief Executive Officer. Other board members are Timothy E. Davis, Jr., John G. Freund, MD, Jeryl Lynn Hilleman, Gregory K. Hinckley, Mika Nishimura, and Thomas A. West. Daniel Wolf joined the board on August 5, 2024, and Laura King was elected as a director on January 13, 2025. This composition reflects a mix of experience and expertise, guiding the company's strategic direction.

The voting structure at SI-Bone, typical for publicly traded companies, operates on a one-share-one-vote basis. The proxy statement from the 2024 Annual Meeting of Stockholders, held on June 25, 2024, detailed proposals for director elections and other corporate matters. Stockholders voted 'For,' 'Against,' or abstained. There are no publicly known individuals or entities with outsized control due to special voting rights. For a deeper dive into the company's origins, you can explore the Brief History of SI-Bone.

SI-Bone Ownership and Voting Rights

SI-Bone's governance structure emphasizes standard voting rights, with each share generally carrying one vote. This approach ensures that all SI-Bone investors have proportional influence based on their shareholdings.

• Directors serve one-year terms.
• Removal of directors requires a 75% stockholder vote.
• Voting operates on a one-share-one-vote basis.
• No special voting rights are publicly highlighted.

SI-Bone Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

In the past few years, the ownership profile of the SI-Bone company has seen shifts, primarily marked by sustained institutional interest. As of May 2025, institutional investors hold a dominant stake of 95.82%, a figure that has remained stable recently. This high level of institutional ownership, which saw a slight increase of 0.1422% in May 2025, suggests continued confidence from large investment firms in SI-Bone. Conversely, insider holdings have shown a slight decrease, moving from 6.32% to 6.04% in May 2025.

For example, in May 2025, CEO Laura Francis sold shares worth $349,134, reducing her direct ownership by 3% to 490,987 units. CFO Anshul Maheshwari also sold shares worth $236,612, decreasing his direct ownership by 4%. This demonstrates a dynamic ownership landscape within the SI-Bone company, with institutional investors maintaining a strong presence while insider holdings experience minor adjustments.

The company's financial results in 2024, with worldwide revenue reaching $167.2 million (a 20% increase from 2023) and positive adjusted EBITDA of $1.9 million in the fourth quarter, likely contributes to continued institutional investment. SI-Bone expects to achieve positive annual adjusted EBITDA in 2025. These financial achievements, combined with ongoing product innovation like the iFuse-3D and iFuse Bedrock Granite systems, are aimed at driving future growth, potentially influencing investor sentiment and ownership trends. The company's participation in healthcare conferences in 2025, such as the Truist Securities MedTech Conference and Goldman Sachs 46th Global Healthcare Conference, indicates active engagement with the investment community.

SI-Bone Ownership Overview

Institutional investors hold a significant majority of SI-Bone shares. Insider ownership has seen a slight decrease recently. The company's financial performance supports investor confidence.

Key Leadership Changes

Laura Francis became CEO in January 2021. Anshul Maheshwari was appointed CFO. New board members were also added. These changes aim to drive future growth.

Financial Performance

2024 revenue reached $167.2 million, a 20% increase. The company achieved positive adjusted EBITDA in Q4 2024. SI-Bone anticipates positive annual adjusted EBITDA in 2025.

Investor Engagement

SI-Bone actively participates in healthcare conferences. This engagement aims to inform the investment community. These activities may influence SI-Bone stock performance.

SI-Bone Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs